Table 2.
4.1B/DAL-1 deficiency in tumors
| Tumor type | Number of cases/cell lines | Number of cases/cell lines with 4.1B/DAL-1 deficiency (%) | References |
|---|---|---|---|
| NSCLC cell lines | 16 | 14 (87) | [81, 91] |
| Adenocarcinoma | 11 | 9 (82) | |
| Squamous cell carcinoma | 1 | 1 (100) | |
| Large cell carcinoma | 3 | 3 (100) | |
| Nonspecified NSCLCs | 1 | 1 (100) | |
| Pleural fluid NSCLC cells | 10 | 9 (90) | |
| SCLC cell lines | 11 | 4 (36) | |
| Primary NSCLC tumors | 39 | 21 (54) | [25] |
| Adenocarcinoma | 15 | 6 (40) | |
| Squamous cell carcinoma | 16 | 11 (69) | |
| Large cell carcinoma | 1 | 1 (100) | |
| Nonspecified NSCLCs | 7 | 3 (43) | |
| Breast cancer | |||
| Breast cancer cell lines | 8 | 6 (75) | [84] |
| Primary breast cancers | 67 | 49 (73) | [78] |
| Lymph node metastasis | |||
| 0 | 46 | 29 (63) | |
| 1–3 | 17 | 16 (94) | |
| ≥4 | 4 | 4 (100) | |
| Lymphovascular invasion | |||
| − | 50 | 33 (66) | |
| + | 17 | 16 (94) | |
| pT stage | |||
| 1 | 31 | 18 (58) | |
| 2 | 33 | 28 (85) | |
| 3 | 3 | 3 (100) | |
| Pathological stage | |||
| I | 23 | 11 (48) | |
| II | 40 | 34 (85) | |
| III | 4 | 4 (100) | |
| Renal clear cell carcinoma | |||
| RCC cell lines | 19 | 10 (53) | [34] |
| Primary RCCC | 19 | 12 (63) | |
| Meningioma | |||
| Benign, non-recurring (grade I) | 20 | 12 (60) | [77] |
| Benign, recurring (grade I) | 16 | 10 (63) | |
| Atypical (grade II) | |||
| High proliferative | 23 | 15 (65) | |
| Brain invasive, low proliferative | 22 | 17 (77) | |
| Anaplastic (grade III) | 7 | 6 (86) | |
| Ovarian cancer | |||
| Ovarian cancer cell lines | 19 | 15 (78) | [39] |
| Benign ovarian tumors | 33 | 8 (24) | |
| Invasive ovarian tumors | 794 | 524 (66) | |
| Clear cell | 61 | 42 (69) | |
| Serous | 454 | 300 (66) | |
| Mucinous | 70 | 43 (61) | |
| Endometrioid | 150 | 86 (57) | |
| Undifferentiated | 38 | 10 (26) | |
| Papillary | 21 | 8 (38) | |